Last Week in Medicine Early Ablation vs Medications for Atrial Fibrillation (STOP-AF First, EARLY-AF), ACEi and ARBs in COVID-19, IV vs Oral Antibiotics for Appendicitis, Rifaximin after TIPS, Low vs High Oxygen Targets
Feb 4, 2021
In this engaging discussion, Dr. Jared Bunch, an electrophysiologist and leading expert in atrial fibrillation, dives into the latest findings from the STOP-AF and EARLY-AF trials. He reveals how early catheter ablation can significantly benefit new AF patients versus traditional medications. The conversation also touches on the safety of continuing ACE inhibitors during COVID-19, the effectiveness of oral antibiotics for uncomplicated appendicitis, and the optimal oxygen targets in respiratory failure. It's a fascinating mix of cutting-edge medical insights!
AI Snips
Chapters
Transcript
Episode notes
Early Rhythm Control Changes AFib Outcomes
- Modern rhythm-control strategies (meds + ablation) can change atrial fibrillation outcomes versus old trials that used ineffective therapies.
- Early intervention with better tools may reduce stroke, heart failure, and mortality risks tied to AFib.
Technique Matters Less Than Operator Skill
- Radiofrequency and cryoballoon ablation produce similar overall outcomes when performed well.
- Choose and master the tool that the operator and center perform best with to optimize results.
Burden Beats Spot Checks
- Implantable monitors capture subclinical AF and provide a more accurate measure of arrhythmia burden than intermittent spot checks.
- Atrial fibrillation burden, not just 30-second recurrences, better reflects patient risk and symptoms.